JP6071012B2 - 4−アミノ−3−フェニルアミノ−6−フェニルピラゾロ[3,4−d]ピリミジン誘導体、その製造および抗ウイルス剤としての使用 - Google Patents
4−アミノ−3−フェニルアミノ−6−フェニルピラゾロ[3,4−d]ピリミジン誘導体、その製造および抗ウイルス剤としての使用 Download PDFInfo
- Publication number
- JP6071012B2 JP6071012B2 JP2014535117A JP2014535117A JP6071012B2 JP 6071012 B2 JP6071012 B2 JP 6071012B2 JP 2014535117 A JP2014535117 A JP 2014535117A JP 2014535117 A JP2014535117 A JP 2014535117A JP 6071012 B2 JP6071012 B2 JP 6071012B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- phenyl
- pyrimidine
- phenylpyrazolo
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003443 antiviral agent Substances 0.000 title claims description 8
- WFQPYBNZEFTXJY-UHFFFAOYSA-N 3-n,6-diphenyl-2h-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical class C1=2C(N)=NC(C=3C=CC=CC=3)=NC=2NN=C1NC1=CC=CC=C1 WFQPYBNZEFTXJY-UHFFFAOYSA-N 0.000 title description 20
- 238000002360 preparation method Methods 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 18
- UOQKALAWEKQAJL-UHFFFAOYSA-N 6-phenyl-3-[4-(trifluoromethyl)phenyl]pyrazolo[3,4-d]pyrimidine-1,4-diamine Chemical compound NC1=C2C(=NC(=N1)C1=CC=CC=C1)N(N=C2C1=CC=C(C=C1)C(F)(F)F)N UOQKALAWEKQAJL-UHFFFAOYSA-N 0.000 claims description 17
- -1 imino (phenyl) methyl substituent Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 claims description 7
- RLLTYDMWCPHMPR-UHFFFAOYSA-N 5-amino-3-anilino-1h-pyrazole-4-carbonitrile Chemical compound N#CC1=C(N)NN=C1NC1=CC=CC=C1 RLLTYDMWCPHMPR-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 208000005155 Picornaviridae Infections Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003495 polar organic solvent Substances 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000126 substance Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 20
- 125000001424 substituent group Chemical group 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 14
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 14
- 229960000471 pleconaril Drugs 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 241000709675 Coxsackievirus B3 Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000000840 anti-viral effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 241000709664 Picornaviridae Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000009525 Myocarditis Diseases 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 206010061494 Rhinovirus infection Diseases 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- WLGYFMHUXDYKEX-UHFFFAOYSA-N 3-n-phenyl-6-[4-(trifluoromethoxy)phenyl]-2h-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical compound C=12C(N)=NC(C=3C=CC(OC(F)(F)F)=CC=3)=NC2=NNC=1NC1=CC=CC=C1 WLGYFMHUXDYKEX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 150000003937 benzamidines Chemical class 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000035495 ADMET Effects 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010014909 Enterovirus infection Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 238000010535 acyclic diene metathesis reaction Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- IWKXBHQELWQLHF-CAPFRKAQSA-N (ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine Chemical class C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=N\O)\C1=CC=CC=C1 IWKXBHQELWQLHF-CAPFRKAQSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000006740 Aseptic Meningitis Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 201000006219 Herpangina Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 206010027201 Meningitis aseptic Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JJDHAOLOHQTGMG-UHFFFAOYSA-N WIN54954 Chemical compound O1N=C(C)C=C1CCCCCOC1=C(Cl)C=C(C=2OCCN=2)C=C1Cl JJDHAOLOHQTGMG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000012022 enterovirus infectious disease Diseases 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VVJYUAYZJAKGRQ-UHFFFAOYSA-N 1-[4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C(O)C1 VVJYUAYZJAKGRQ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical class CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- FICQFRCPSFCFBY-UHFFFAOYSA-N 2-[bis(methylsulfanyl)methylidene]propanedinitrile Chemical compound CSC(SC)=C(C#N)C#N FICQFRCPSFCFBY-UHFFFAOYSA-N 0.000 description 1
- KFVFSHVEAMTYFQ-UHFFFAOYSA-N 2h-pyrazolo[3,4-d]pyrimidin-3-amine Chemical compound C1=NC=C2C(N)=NNC2=N1 KFVFSHVEAMTYFQ-UHFFFAOYSA-N 0.000 description 1
- XWJMBQVJKKZBDC-UHFFFAOYSA-N 3-(4-chlorophenyl)-6-phenylpyrazolo[3,4-d]pyrimidine-1,4-diamine Chemical compound NC1=C2C(=NC(=N1)C1=CC=CC=C1)N(N=C2C1=CC=C(C=C1)Cl)N XWJMBQVJKKZBDC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SBUTUXPBDZNLBB-UHFFFAOYSA-N 3-n-(3-fluorophenyl)-6-phenyl-2h-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical compound C1=2C(N)=NC(C=3C=CC=CC=3)=NC=2NN=C1NC1=CC=CC(F)=C1 SBUTUXPBDZNLBB-UHFFFAOYSA-N 0.000 description 1
- SUQFRGGGPHBXKV-UHFFFAOYSA-N 3-n-(4-chlorophenyl)-6-phenyl-2h-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical compound C1=2C(N)=NC(C=3C=CC=CC=3)=NC=2NN=C1NC1=CC=C(Cl)C=C1 SUQFRGGGPHBXKV-UHFFFAOYSA-N 0.000 description 1
- PGRDMBPYJARRFL-UHFFFAOYSA-N 3-n-(4-fluorophenyl)-6-phenyl-2h-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical compound C1=2C(N)=NC(C=3C=CC=CC=3)=NC=2NN=C1NC1=CC=C(F)C=C1 PGRDMBPYJARRFL-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 description 1
- BWNQXEULXYMARU-UHFFFAOYSA-N 5-amino-3-(3-fluoroanilino)-1h-pyrazole-4-carbonitrile Chemical compound N#CC1=C(N)NN=C1NC1=CC=CC(F)=C1 BWNQXEULXYMARU-UHFFFAOYSA-N 0.000 description 1
- FNPXPDHYRVGBPS-UHFFFAOYSA-N 5-amino-3-(4-fluoroanilino)-1h-pyrazole-4-carbonitrile Chemical compound N#CC1=C(N)NN=C1NC1=CC=C(F)C=C1 FNPXPDHYRVGBPS-UHFFFAOYSA-N 0.000 description 1
- CDCWTSPCOGVZJU-UHFFFAOYSA-N 6-phenyl-1h-pyrazolo[3,4-d]pyrimidine Chemical class N=1C=C2C=NNC2=NC=1C1=CC=CC=C1 CDCWTSPCOGVZJU-UHFFFAOYSA-N 0.000 description 1
- SKHGWHSPAVBQRK-UHFFFAOYSA-N 6-phenyl-2h-pyrazolo[3,4-d]pyrimidin-3-amine Chemical compound N1=CC2=C(N)NN=C2N=C1C1=CC=CC=C1 SKHGWHSPAVBQRK-UHFFFAOYSA-N 0.000 description 1
- HYUDDHSPJFCULQ-UHFFFAOYSA-N 6-phenyl-3-n-[4-(trifluoromethyl)phenyl]-2h-pyrazolo[3,4-d]pyrimidine-3,4-diamine Chemical compound C=12C(N)=NC(C=3C=CC=CC=3)=NC2=NNC=1NC1=CC=C(C(F)(F)F)C=C1 HYUDDHSPJFCULQ-UHFFFAOYSA-N 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108010076278 Adenosine kinase Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000037874 Asthma exacerbation Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 102100021752 Corticoliberin Human genes 0.000 description 1
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 241000709698 Coxsackievirus A21 Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000709714 Echovirus E11 Species 0.000 description 1
- 241001529459 Enterovirus A71 Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- PCWOLALRCGBTHX-UHFFFAOYSA-N FC=1C=C(C=CC1F)NC=1NN=C2N=C(N=C(C21)N)C2=CC=CC=C2.NC2=C1C(=NC(=N2)C2=CC=CC=C2)N(N=C1C1=CC(=C(C=C1)F)F)N Chemical compound FC=1C=C(C=CC1F)NC=1NN=C2N=C(N=C(C21)N)C2=CC=CC=C2.NC2=C1C(=NC(=N2)C2=CC=CC=C2)N(N=C1C1=CC(=C(C=C1)F)F)N PCWOLALRCGBTHX-UHFFFAOYSA-N 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000709716 Human enterovirus 70 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- JORCVTZTMUQFGU-UHFFFAOYSA-N Nc1c(c(Nc2ccc(C(F)(F)F)cc2)n[n]2C(c3ccccc3)=N)c2nc(-c2ccccc2)n1 Chemical compound Nc1c(c(Nc2ccc(C(F)(F)F)cc2)n[n]2C(c3ccccc3)=N)c2nc(-c2ccccc2)n1 JORCVTZTMUQFGU-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- BQVJCMMLDJPBFZ-UHFFFAOYSA-N [amino(phenyl)methylidene]azanium;chloride;hydrate Chemical compound O.Cl.NC(=N)C1=CC=CC=C1 BQVJCMMLDJPBFZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000005180 acute myocarditis Diseases 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002128 anti-rhinoviral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940124765 capsid inhibitor Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 229950008161 enviroxime Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Chemical class 0.000 description 1
- 239000001630 malic acid Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Description
フェニル基AおよびBの各々の中の全てのさらなる水素原子は互いに独立に、R1残基により置き換えられていてもよく、
各R1は独立に、ハロゲン、1〜7個の鎖構成(kettengliedern)を有する飽和もしくは不飽和、直鎖もしくは分枝脂肪族遊離基、1〜8個の鎖構成を有する飽和もしくは不飽和、直鎖もしくは分枝アルカノール(alkanoles)遊離基、NO2、CN、CONR2 2、COR2、COOR2、OR2、SR2、NR2 2、SO2NR2 2、CX3、CR2X2、OCX3、OCR2X2またはフェニルであってもよく;
各R2は独立に、水素、1〜7個の鎖構成を有する飽和もしくは不飽和、ハロゲン化もしくは非ハロゲン化、直鎖もしくは分枝脂肪族遊離基、ベンジル、フェニルまたはナフチル、ヘテロ原子N、SもしくはOを有する飽和もしくは不飽和、モノ−もしくはポリ複素環であり、上記基の各々は独立に、フッ素、塩素、臭素、トリフルオロメチル、アルキル、アルコキシ、シアノ、ニトロ、アミノ、アミノアルキル、C(O)−アルキル、C(O)O−アルキル、ベンジル、フェニルまたはナフチルで置換されていてもよく;
Xは独立に、F、Cl、BrまたはIである。
σX=logKX−logKH
式中、KHは25℃水中での安息香酸についてのイオン化定数であり、KXはメタまたはパラ置換安息香酸についての対応する定数である、安息香酸のイオン化定数に基づく。メタ位(σm)およびパラ位(σp)の異なる置換基についてのハメット定数を決定する方法ならびに種々の置換基の既に確認された値は、全体が本明細書に組み込まれている、Hansch et al.,「A Survey of Hammett Substituent Constants and Resonance and Field Parameters」,in Chem.Rev.1991.97,165−195の刊行物から引用することができる。したがって、少なくとも1つの置換基RHが最終的に位置している位置にかかわらず、パラ位についてのそれぞれの値σ(σp)がもっぱら本発明に重要である。
CRCV−340−プロドラッグ
を有する、上記化合物CRCV−340の製造の副産物に関連する。
5−アミノ−4−シアノ−3−フェニルアミノピラゾールを、図解1(Abb.1)に示す方法ならびにTominaga Yら(J.Heterocycl.Chem.,1990,27,775−779)の説明にしたがって合成した。アリールアミジンを、対応するシアン源化合物から既知の先行技術にしたがって合成する(Boere,RT et al.:J.Organomet.Chem.,1987,331,161−167;Garigipati RS:Tetrahedron Lett.,1990,31,1969−1978;Dann O et al.:Justus Liebigs Ann.Chem.,1982,1836−1839)。
特性:融点:265〜267℃(テトラヒドロフラン);MS(m/z)302(M+);1H NMR(DMSO−d6):δ12.38(1H、s、NH)、8.30〜8.36(2H、q、2CH)、8.23(1H、br.s.、NH)、7.67(2H、d、2CH)、7.48(2H、br.s.、NH2)、7.42(3H、m、3CH)、7.12(2H、d、2CH)および6.98(1H、m、CH)ppm;元素分析C17H14N6:計算%:C、67.54;H、4.67;N,27.80;実測%:C、67.49;H、4.53;N、27.74。
特性:融点:262〜263℃(THF/トルエン);MS(m/z):320(M’);1H NMR(DMSO−d6):δ12.69(1H、s、NH)、8.33〜8.41(4H、m、4CH)、8.18(1H、br.s.、NH)、7.58〜7.65(5H、m、NH2、3CH)、7.27〜7.31(2H、n、2CH)ppm;元素分析C17H14FN6:計算%:C、63.74;H、4.09;N、26.24;実測%:C、63.81;H、4.11;N、26.27。
特性:融点:278〜279℃(THF/トルエン);MS(m/z):320(M+);1H NMR(DMSO−d6):δ12.61(1H、s、NH)、8.34〜8.42(2H、q、2CH)、8.14(1H、br.s.、NH)、7.48(2H、br.s.、NH2)、7.3〜7.43(6H、m、6CH)、6.60(1H、s、CH)ppm;元素分析C17H14FN6:計算%:C、63.74;H、4.09;N、26.24;実測%:C、63.81;H、4.11;N、26.27。
特性:融点:313〜314℃(THF/トルエン);MS(m/z):370(M+);1H NMR(DMSO−d6):δ12.77(1H、s、NH)、8.91(1H、s、NH)、8.47(2H、s、NH2)、7.81、7.79、7.63、7.58および7.47(9H、m、C6H4およびC6H5)ppm;元素分析C18H13F3N6:計算%:C、58.38;H、3.54;N、22.69;実測%:C、58.41;H、3.58;N、22.74;HPLC:99.30%(Saule Luna C18(2)、アセトニトリル/水−90:10、流れ0.6ml/分、UV254nm;tR=5.3分)
特性:融点:260〜262℃(テトラヒドロフラン/DMF);MS(m/z):386(M’);1H NMR(DMSO−d6):δ12.56(1H、s、NH)8.82(2H、q、2CH)、8.16(1H、br.s.、NH)、7.48(2H、br.s.、NH2)、7.3〜7.43(4H、m、C6H5)、7.05〜7.11(2H、2s、2CH)、6.98(1H、m、CH)ppm;元素分析C18H13F3N6O:計算%:C、55.96;H、3.39;N、21.75;実測%:C、56.07;H、3.36;N、21.61。
HPLC:99.16%(Saule Luna C18(2)、アセトニトリル/水−90:10、流れ0.6ml/分、UV254nm;tR=5.3分)
目的:インビトロでのOBR5−340の吸収、分布、代謝、排出および毒性(ADMETと略す)を調査すること、ならびに血漿タンパク質結合と血漿および肝ミクロソーム中でのおよび安定性についてのインビトロ試験
試験:CRCV−340で行ったインビトロ試験ならびに得られたデータを、参考2と比較して表2に要約する。
目的:CRCV−340についての薬物動態データを回収すること。
試験:物質および参考物質を、10%Cremophor溶液0.5ml中、100mg/kg KGの濃度でマウスに経口的にそれぞれ1回施用した。0.5、1、2、3、4、5、6および7時間後、血清を採取し、HPLC分析により、マウスの血漿中のCRCV−340、参考−2および参考−3の濃度を測定した。
Tmax 血中最大濃度に達するまでの時間
MRT 平均滞留時間
T1/2 半減期
Kel 排出速度定数
CL クリアランス
Vd 分布容積
AUC 曲線下面積
Cmax/AUC 胃から血液への吸収速度
結果:CRCV−340についてのマウスにおける薬物動態についての試験により、参考−2および参考−3よりも有意に優れた生物学的利用能が得られた。
目的:CRCV−340の50%致死量を決定すること。
試験:物質CRCV−340の急性毒性を、体重19.5〜20.5gのマウスで試験した。この物質を、40、60、80または120mg物質/マウス(1物質および1濃度当たり5匹のマウス)で経口投与した。これは、体重1kg当たり約2g、3g、4gまたは6gの用量に相当する。結果で認められた毒性効果は、投与した物質量に相関していた。物質を投与した最大3時間後に40および60mg/マウスの用量で、協調障害および活動亢進が副作用として観察された。2つのより高用量の投与後には、呼吸困難、攻撃行動および運動亢進もあった。CRCV−340については、3120mg/kgのLD50が決定された(表4)。
目的:28日間にわたるCRCV−340の亜急性投与により生じるおそれがある、例えば、全身状態、体重、内臓および代謝に対する可能な副作用を明らかにするために、マウスにおける亜急性毒性を決定すること。
試験:例えば、体重約20gの雄および雌マウスは、チューブを通して胃内投与で1日1回28日間にわたって、12.5、50または200mg/kgのCremophor製剤中物質CRCV−340を受け、コントロール群は、Cremophorを受けた。実験の全期間中、毛皮および粘膜の状態、***物、ならびに全身状態を評価した。体重の記録は7、14、21および28日に行った。最後の物質投与の約24時間後、動物の方向感覚を検査した。血清中の以下の生化学的パラメータを分析した:タンパク質含量、尿素、クレアチニン、アスパラギン酸アミノトランスフェラーゼ、アラニンアミノトランスフェラーゼおよびアルカリホスファターゼの血清活性。ヘモグロビン濃度、ヘマトクリット、赤血球および白血球ならびに血小板の数を血液塗抹標本で測定した。実験の最後に、マウスを麻酔下でと殺および解剖し、内臓の状態を巨視的に評価し、臓器重量を決定し、その後の組織学的試験用の試料をホルマリンに漬け込んだ。
目的:50種の異なるヒトライノウイルス血清型およびCVB3患者分離株に関するCRCV−340の抗ウイルス有効スペクトルを決定すること。
試験:50種のHRV血清型および20種の臨床CVB3分離株を、HeLa、HeLa Wisおよび/またはLF細胞で増殖させ、その力価を決定し、配列決定を使用して血清型を確認した。こうして、HRVを用いたzpE(細胞変性(zytopathischer)効果)阻害試験またはCVB3分離株を用いたプラーク減少試験を確立した。対応する抗ウイルス試験では、参考−3およびCRCV−340を用いた用量効果試験を行った。表5および6は、平均50%阻害濃度の概要を説明する。
結果要約:HRVに関するCRCV−340の有効スペクトルは、参考−3と比較して有意に広かった。
試験:CRCV−340の効果を、8週齢雄NMRIマウスのCVB3−誘発型心筋炎のモデルで試験した。さらに、CVB3 31−1−93またはCVB3 H3−感染動物に、水(プラセボ)中1%CMC中50%または20%PEG−400中100mg/kgの物質を1日1回または2回、7日間にわたって投与した。治療効果を評価するためのパラメータには、体重、全身状態、心臓および膵臓組織におけるウイルス力価の変化ならびに心臓および膵臓における病理組織学的変化が含まれていた。感染の経過にわたって、偽感染、プラセボ処置またはCRCV−340処置動物がネガティブコントロールとして作用し、感染、プラセボ−またはプレコナリル処置動物がポジティブコントロールとして作用する。
試験:開発候補薬CRCV−340の効果を、6〜7週齢雄BALB/cマウスのCVB−誘発型心筋炎のモデルで感染量の試験後に試験した。さらに、CVB3 31−1−93またはCVB3 H3−感染動物に、水(プラセボ)中1%CMC中20%PEG−400中100mg/kgの物質を1日2回、7日間にわたって投与した。体重、全身状態、代用マーカー、体重の25%損失を通して定義される致死率が、治療効果を評価するためのパラメータとして作用した。感染の経過にわたって、偽感染、プラセボ−処置またはCRCV−340−処置動物がネガティブコントロールを表し、感染、プラセボ−またはプレコナリル−処置動物がポジティブコントロールを表した。
Claims (11)
- 請求項1記載の4−アミノ−3−(4−トリフルオロメチル−フェニル)アミノ−6−フェニルピラゾロ[3,4−d]ピリミジンを含む医薬組成物。
- 薬学的に許容される担体も含む、請求項2に記載の医薬組成物。
- 1種または数種の他の有効成分も含む、請求項2または3に記載の医薬組成物。
- 前記1種または数種の他の有効成分が抗ウイルス剤である、請求項4に記載の医薬組成物。
- 薬学的に許容される担体による請求項1記載の4−アミノ−3−(4−トリフルオロメチル−フェニル)アミノ−6−フェニルピラゾロ[3,4−d]ピリミジンの製剤化を含む、医薬組成物を製造する方法。
- 薬物として使用するための、請求項1記載の4−アミノ−3−(4−トリフルオロメチル−フェニル)アミノ−6−フェニルピラゾロ[3,4−d]ピリミジン。
- ウイルス感染症の予防的または治療的処置に使用するための、請求項1記載の4−アミノ−3−(4−トリフルオロメチル−フェニル)アミノ−6−フェニルピラゾロ[3,4−d]ピリミジン。
- 前記ウイルス感染症がピコルナウイルス感染症であるという事実により特徴付けられる、請求項8に記載の4−アミノ−3−(4−トリフルオロメチル−フェニル)アミノ−6−フェニルピラゾロ[3,4−d]ピリミジン。
- 極性有機溶媒中での、遊離塩基のベンズアミジンによる5−アミノ−4−シアノ−3−フェニルアミノピラゾールの変換を含む、4−アミノ−3−(4−トリフルオロメチル−フェニル)アミノ−6−フェニルピラゾロ[3,4−d]ピリミジンを製造する方法。
- 前記4−アミノ−3−(4−トリフルオロメチル−フェニル)アミノ−6−フェニルピラゾロ[3,4−d]ピリミジンが、次いで、テトラヒドロフランまたはその水もしくは有機溶媒との混合物を使用した再結晶により、あるいはテトラヒドロフランと水または有機溶媒中熱溶液を使用した沈殿により再結晶される、請求項10に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE201110116373 DE102011116373A1 (de) | 2011-10-14 | 2011-10-14 | Methode zur Herstellung von 4-Amino-3-arylamino-6-arylpyrazolo[3, 4-d]pyrimidinen |
DE102011116373.9 | 2011-10-14 | ||
DE102011116384.4 | 2011-10-20 | ||
DE102011116384 | 2011-10-20 | ||
PCT/EP2012/070403 WO2013053942A1 (de) | 2011-10-14 | 2012-10-15 | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidin-derivate, deren herstellung und deren verwendung als antivirale wirkstoffe |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014528468A JP2014528468A (ja) | 2014-10-27 |
JP6071012B2 true JP6071012B2 (ja) | 2017-02-01 |
Family
ID=47071252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014535117A Active JP6071012B2 (ja) | 2011-10-14 | 2012-10-15 | 4−アミノ−3−フェニルアミノ−6−フェニルピラゾロ[3,4−d]ピリミジン誘導体、その製造および抗ウイルス剤としての使用 |
Country Status (22)
Country | Link |
---|---|
US (1) | US9790225B2 (ja) |
EP (1) | EP2766367B1 (ja) |
JP (1) | JP6071012B2 (ja) |
KR (1) | KR20140095467A (ja) |
CN (1) | CN103946224A (ja) |
AU (1) | AU2012322750B2 (ja) |
BR (1) | BR112014008815B1 (ja) |
CA (1) | CA2850439C (ja) |
DK (1) | DK2766367T3 (ja) |
ES (1) | ES2924828T3 (ja) |
HR (1) | HRP20220928T1 (ja) |
HU (1) | HUE059217T2 (ja) |
IL (1) | IL231934A (ja) |
LT (1) | LT2766367T (ja) |
MX (1) | MX2014003987A (ja) |
PL (1) | PL2766367T3 (ja) |
PT (1) | PT2766367T (ja) |
RU (1) | RU2014118953A (ja) |
SG (2) | SG11201401351PA (ja) |
SI (1) | SI2766367T1 (ja) |
WO (1) | WO2013053942A1 (ja) |
ZA (1) | ZA201402226B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3064207B1 (en) * | 2015-03-04 | 2017-12-20 | Scandion Oncology A/S | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments |
KR102205570B1 (ko) | 2018-09-12 | 2021-01-20 | 김홍기 | 뿌리식물 수경재배용 시트 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2965643A (en) | 1960-12-20 | Derivatives of pyrazolo | ||
US3551428A (en) | 1956-02-10 | 1970-12-29 | Ciba Geigy Corp | New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines |
DE3712735A1 (de) | 1987-04-15 | 1988-11-10 | Boehringer Mannheim Gmbh | Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel |
CA2100863A1 (en) | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
US5646152A (en) | 1994-06-15 | 1997-07-08 | Pfizer Inc. | Methods of administering CRF antagonists |
CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
DE102006029074A1 (de) * | 2006-06-22 | 2007-12-27 | Friedrich-Schiller-Universität Jena | 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe |
-
2012
- 2012-10-15 PT PT127756591T patent/PT2766367T/pt unknown
- 2012-10-15 PL PL12775659.1T patent/PL2766367T3/pl unknown
- 2012-10-15 SG SG11201401351PA patent/SG11201401351PA/en unknown
- 2012-10-15 CA CA2850439A patent/CA2850439C/en active Active
- 2012-10-15 LT LTEPPCT/EP2012/070403T patent/LT2766367T/lt unknown
- 2012-10-15 HU HUE12775659A patent/HUE059217T2/hu unknown
- 2012-10-15 RU RU2014118953/04A patent/RU2014118953A/ru not_active Application Discontinuation
- 2012-10-15 JP JP2014535117A patent/JP6071012B2/ja active Active
- 2012-10-15 US US14/350,885 patent/US9790225B2/en active Active
- 2012-10-15 BR BR112014008815-2A patent/BR112014008815B1/pt active IP Right Grant
- 2012-10-15 CN CN201280050298.6A patent/CN103946224A/zh active Pending
- 2012-10-15 KR KR1020147009385A patent/KR20140095467A/ko not_active Application Discontinuation
- 2012-10-15 SG SG10201602846TA patent/SG10201602846TA/en unknown
- 2012-10-15 MX MX2014003987A patent/MX2014003987A/es unknown
- 2012-10-15 DK DK12775659.1T patent/DK2766367T3/da active
- 2012-10-15 HR HRP20220928TT patent/HRP20220928T1/hr unknown
- 2012-10-15 SI SI201232005T patent/SI2766367T1/sl unknown
- 2012-10-15 WO PCT/EP2012/070403 patent/WO2013053942A1/de active Application Filing
- 2012-10-15 EP EP12775659.1A patent/EP2766367B1/de active Active
- 2012-10-15 AU AU2012322750A patent/AU2012322750B2/en active Active
- 2012-10-15 ES ES12775659T patent/ES2924828T3/es active Active
-
2014
- 2014-03-26 ZA ZA2014/02226A patent/ZA201402226B/en unknown
- 2014-04-03 IL IL231934A patent/IL231934A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SG11201401351PA (en) | 2014-08-28 |
RU2014118953A (ru) | 2015-11-20 |
BR112014008815A2 (pt) | 2017-04-25 |
SI2766367T1 (sl) | 2022-10-28 |
SG10201602846TA (en) | 2016-05-30 |
WO2013053942A1 (de) | 2013-04-18 |
NZ623573A (en) | 2016-08-26 |
BR112014008815B1 (pt) | 2021-01-12 |
PL2766367T3 (pl) | 2022-08-22 |
EP2766367A1 (de) | 2014-08-20 |
PT2766367T (pt) | 2022-08-12 |
MX2014003987A (es) | 2014-09-22 |
JP2014528468A (ja) | 2014-10-27 |
AU2012322750A1 (en) | 2014-04-24 |
DK2766367T3 (da) | 2022-08-01 |
EP2766367B1 (de) | 2022-05-18 |
KR20140095467A (ko) | 2014-08-01 |
IL231934A0 (en) | 2014-05-28 |
LT2766367T (lt) | 2022-08-25 |
HRP20220928T1 (hr) | 2022-10-28 |
AU2012322750B2 (en) | 2016-11-10 |
ES2924828T3 (es) | 2022-10-11 |
CA2850439C (en) | 2020-04-07 |
ZA201402226B (en) | 2015-05-27 |
US20140296259A1 (en) | 2014-10-02 |
IL231934A (en) | 2017-03-30 |
CA2850439A1 (en) | 2013-04-18 |
CN103946224A (zh) | 2014-07-23 |
US9790225B2 (en) | 2017-10-17 |
HUE059217T2 (hu) | 2022-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006203828B2 (en) | CXCR4 antagonists for the treatment of medical disorders | |
JP6915911B2 (ja) | Rnaおよび/またはdna含有ウイルスにより引き起こされる疾患と合併症の治療および予防のための薬剤としてのアミド化合物、およびその使用 | |
CA2935658C (en) | Pyrazolo[1,5-a]pyrimidin-7-amine derivatives useful in therapy | |
RU2770363C2 (ru) | Гетероароматические соединения, пригодные в терапии | |
KR20200069381A (ko) | 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법 | |
JP5171815B2 (ja) | 4−アミノ−3−アリールアミノ−6−アリールピラゾロ[3,4−d]ピリミジン誘導体、その製造方法及び抗ウイルス性作用物質としての使用 | |
JP6071012B2 (ja) | 4−アミノ−3−フェニルアミノ−6−フェニルピラゾロ[3,4−d]ピリミジン誘導体、その製造および抗ウイルス剤としての使用 | |
WO2014134750A1 (zh) | 2,6,9-三取代嘌呤衍生物及其制备方法与应用 | |
BR112021015813A2 (pt) | Derivado de 7h-pirrolo[2,3-d]pirimidina-4-amina | |
NZ623573B2 (en) | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d] pyrimidine derivatives, manufacture and their use as antiviral active substances | |
DE102012004736A1 (de) | 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidin-Derivate und deren Verwendung als antivirale Wirkstoffe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151009 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160422 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160712 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161209 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161221 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6071012 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |